首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF20 |
| Uniprot No | Q9NP95 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-211aa |
| 氨基酸序列 | MAPLAEVGGF LGGLEGLGQQ VGSHFLLPPA GERPPLLGER RSAAERSARG GPGAAQLAHL HGILRRRQLY CRTGFHLQIL PDGSVQGTRQ DHSLFGILEF ISVAVGLVSI RGVDSGLYLG MNDKGELYGS EKLTSECIFR EQFEENWYNT YSSNIYKHGD TGRRYFVALN KDGTPRDGAR SKRHQKFTHF LPRPVDPERV PELYKDLLMY T |
| 预测分子量 | 23,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGF20重组蛋白的模拟参考文献示例(内容基于公开研究领域概括，非真实文献)：
---
1. **《FGF20重组蛋白促进毛囊发育的体外研究》**
*作者：Smith A, et al.*
摘要：研究证明重组FGF20蛋白通过激活MAPK信号通路，显著增强毛囊干细胞增殖，提示其在脱发治疗中的潜在应用价值。
2. **《FGF20对多巴胺能神经元的保护作用》**
*作者：Chen L, et al.*
摘要：实验发现重组FGF20能抑制帕金森病模型中神经元凋亡，并通过调节抗氧化通路减轻氧化应激损伤，为神经退行性疾病治疗提供新思路。
3. **《高效表达FGF20重组蛋白的工程菌构建》**
*作者：Wang Y, et al.*
摘要：开发了一种新型大肠杆菌表达系统，成功实现FGF20的高效可溶性表达，并验证其生物活性，为规模化生产奠定基础。
4. **《FGF20通过调控Wnt/β-catenin通路影响肿瘤转移》**
*作者：Kimura T, et al.*
摘要：研究发现癌细胞分泌的FGF20重组蛋白可激活肿瘤微环境中的Wnt通路，促进上皮-间质转化(EMT)，提示其作为癌症治疗靶点的潜力。
---
*注：以上内容为领域知识概括性模拟，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。*
Fibroblast Growth Factor 20 (FGF20) is a member of the FGF family, a group of signaling proteins involved in diverse biological processes such as embryonic development, tissue repair, and metabolic regulation. Belonging to the FGF9 subfamily, FGF20 is distinguished by its paracrine signaling mechanism, requiring heparan sulfate proteoglycans to activate FGF receptors (FGFRs). It primarily binds to FGFR1c, FGFR2c, and FGFR3c, triggering downstream pathways like MAPK and PI3K-AKT to regulate cell proliferation, differentiation, and survival.
Recombinant FGF20 is produced using genetic engineering techniques, often expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Its stable, purified form enables research and therapeutic applications. Studies highlight FGF20's role in neuroprotection, particularly in Parkinson’s disease, where it supports dopaminergic neuron survival in the substantia nigra. Additionally, it influences hair follicle development and wound healing, with potential applications in regenerative medicine and alopecia therapies.
Research also explores FGF20's association with cancer, as aberrant expression may promote tumor growth in certain contexts. However, its therapeutic use remains focused on neurogenerative and tissue-repair applications. Recombinant FGF20 serves as a critical tool for dissecting these pathways and developing targeted treatments, balancing efficacy with safety in preclinical models. Ongoing studies aim to optimize delivery methods and minimize off-target effects, underscoring its dual role as a biomarker and therapeutic agent in complex diseases.
×
